Psychiatry Clinics news desk
Original reporting based on FDA materials, official REMS information, peer-reviewed research, and other named primary sources.
Treatment updates
The 2025 FDA label expansion allows SPRAVATO® alone for adults with treatment-resistant depression. Supervised treatment and safety requirements still apply.
October 13, 2026 · Source: FDA supplemental approval letter
Read the updateLatest reporting
October 13, 2026
Cobenfy’s 2024 approval added a muscarinic-based option for adults with schizophrenia. Here is what the trials and current safety labeling can—and cannot—tell patients.
Primary source: FDA Drug Trials Snapshot: Cobenfy
News tells you what changed. These guides explain approved uses, treatment options, safety, insurance, and questions to ask a psychiatric clinic.
